Quantum-Si Incorporated (QSI) Q3 2024 Earnings Call Transcript Summary
Quantum-Si Incorporated (QSI) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Quantum-Si Incorporated (QSI) Q3 2024 Earnings Call Transcript:
以下是量子硅公司(QSI)2024年第三季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Third quarter 2024 revenue was below expectations at $787,000.
Gross profit was $367,000 and gross margin stood at 47%.
Net loss for the quarter amounted to $25.3 million, and adjusted EBITDA was negative $24.5 million.
2024年第三季度的收入低於預期,爲78.7萬美元。
毛利爲36.7萬美元,毛利率爲47%。
該季度的淨虧損爲2530萬美元,調整後的息稅折舊攤銷前利潤爲負2,450萬美元。
Business Progress:
業務進展:
Significant strides in commercial ramp-up of 'Platinum', aiming to lead the proteomics market.
Introduced key strategic hires and improved sales process to accelerate commercial adoption.
Added new library preparation and barcoding kits enhancing functionality and reduction in sample prep time.
Received the Technology Innovation Leadership Award from Frost & Sullivan for pioneering proteomic research.
Partnered with University of California, Santa Cruz, to integrate Platinum with genomic and transcriptomic data.
「鉑金」 的商業化發展取得了重大進展,旨在引領蛋白質組學市場。
引入了關鍵戰略人才並改進了銷售流程,以加快商業採用。
增加了新的文庫製備和條形碼套件,增強了功能並縮短了樣本製備時間。
因開創性的蛋白質組學研究獲得弗羅斯特沙利文頒發的技術創新領導力獎。
與加州大學聖克魯斯分校合作,將鉑金與基因組和轉錄組學數據整合。
Opportunities:
機會:
Positioned to benefit from potential end year capital spending boosts in the industry.
New advancements in technology expected to open large, new market opportunities and position the company prominently in proteomics.
有望從該行業潛在的年底資本支出增加中受益。
新的技術進步有望開闢廣闊的新市場機會,並使公司在蛋白質組學領域佔據突出地位。
Risks:
風險:
Significant lengthening of the sales cycle experienced, with some deals being pushed back, impacting revenue predictability.
銷售週期顯著延長,一些交易被推遲,影響了收入的可預測性。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
小貼士:本文由 AI 生成。無法完全保證內容的準確性。如需更全面的詳情,請訪問投資者關係網站。本文僅供投資者參考,不提供任何指導或建議建議。